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Glioblastomas are high-grade, malignant CNS neoplasms that are nearly always fatal within 12 months of diagnosis.
Immunotherapy using proinﬂammatory cytokines such as IL-2 or IL-12 may prolong survival with glioblastoma. Thymosin-α1
(Talpha1) is a thymic hormone and immunemodulator that increase IL-2 production and T-cell proliferation. We examined
potential therapeutic eﬀects of Talpha1 in experimental in vivo glioblastoma, and characterized Talpha1’s anti-tumor eﬀects in
vitro. Rar 9L cells (104) were implanted into the right frontal lobe of adult Long Evans rats that were subsequently treated with
vehicle, BCNU, Talpha1, or Talpha1+BCNU from postoperative day 6. Talpha1+BCNU signiﬁcantly lowered tumor burdens, and
increased cure rates. In vitro experiments demonstrated that Talpha1 had no direct eﬀect on viability or mitochondrial function,
and instead, it increased expression of pro-apoptosis genes, including FasL, FasR and TNFα-R1 (65.89%, 44.08%, and 22.18%,
resp.), and increased 9L cell sensitivity to oxidative stress. Moreover, Talpha1 enhanced 9L cell sensitivity to both Granzyme B-
and BCNU-mediated killing. The ﬁndings suggest that Talpha1 enhances BCNUmediated eradication of glioblastoma in vivo, and
that Talpha1 mediates its eﬀects by activating pro-apoptosis mechanisms, rendering neoplastic cells more sensitive to oxidative
stress and immune-mediated killing by Granzyme B and chemotherapeutic agents.
Copyright © 2009 Arno Sungarian et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Glioblastoma is the most common primary CNS malignant
neoplasm in adults, accounting for nearly 75% of the cases.
Despite steady progress in treatment due to improvements in
neuro-imaging, microsurgery, and radiation, glioblastomas
remain incurable [1–5] .T h em e a ns u r v i v a lr a t ei sl e s s
than one year from diagnosis, and the ﬁve-year survival
rate following aggressive therapy including gross tumor
resection is less than 10% [1, 6–8]. Glioblastomas cause
death due to rapid, aggressive, and inﬁltrative growth, which
rendersthetumorsunresectableintoto.Additionalproblems
compounding treatment and cure are that glioblastomas are
relatively resistant to radiation and chemotherapy [1, 2, 6–
9], and the host immune response to the tumors is likely
to be ineﬀective in eradicating even small populations of
neoplasticcellsthatremainfollowingconventionaltreatment
including surgery [10–12].
Malignant glioma cells can evade detection by the
host’s immune system by producing immunosuppressive
peptides that impair T-cell functions such as proliferation
and production of IL-2 [10]. The CNS is also somewhat
immune privileged, which contributes to the unfettered
growth of malignant neoplastic cells. Immunotherapy or
treatment by recruitment of the immune system to kill
malignant neoplastic cells has been researched in many
models. Thymosin fraction 5 (TF5), thymosin-α1( T a l -
pha1/thymalfasin), IFN-α, and IL-2 are among the many
immune-relatedcomponentsthathavebeenstudiedfortheir
abilities to ﬁght malignant neoplasms. Talpha1 is a 28-amino
acid peptide, and a synthetic form of a naturally occurring
hormone that circulates in the thymus [13–15]. Talpha1 and
thymic peptide hormones stimulate thymocyte growth and
diﬀerentiation, production of IL-2, T cell IL-2 receptors,
IFN-γ and IFN-α [16–26]. Talpha1 has been used in clinical
trials to treat Hepatitis B and Hepatitis C virus infections2 Journal of Oncology
[13, 27–34], malignant neoplasms [14, 15, 35], cytome-
galovirus infection following renal transplant [36], and
AIDS [13]. The promising results of these investigations,
combined with the evidence of reduced T-cell responsiveness
to glioblastomas, led to the present work evaluating the
potential therapeutic beneﬁt of Talpha1 immunotherapy for
treating malignant gliomas, and determining the mecha-
nisms in which Talpha1 exerts its antineoplastic eﬀects.
2.ExperimentalDesign
2.1. In Vivo Studies. Experiments were designed to deter-
mine if Talpha1 delivered alone or in combination with Bis-
chloroethylnitrosourea (BCNU) could signiﬁcantly reduce
glioblastoma burden compared with BCNU treatment alone.
Experiments were conducted using an in vivo model of
glioblastomageneratedinadult(250–300grams)LongEvans
rats. Rats were anesthetized with a single intraperitoneal
injection of 100mg/kg xylazine and 15mg/kg ketamine in
14.2%ethanol.Underdeepanesthesia,theheadswereshaved
and prepped with povidone iodine and the rats were securely
positioned in a stereotaxic frame. A midline incision was
made and a 3mm burr hole was drilled over the right
frontal lobe. A Hamilton syringe equipped with a 26-gauge
needle was ﬁxed at the center of the burr hole. The needle
was placed at a depth of 3.5mm for injection of 1 × 104
cells in a volume of 2μL. After removing the needle, the
wound was washed with sterile saline and the skin was closed
with self-resorbing sutures. The rats were returned to their
cages and observed for any signs of deterioration including
weight loss, reduced food and water intake, hemiplegia,
seizures, or inactivity. Empiric studies demonstrated that
intracerebral injection of 10,000 9L cells kills 100% of the
rats within 21–24 days of implantation. These studies were
approved by the Lifespan/Rhode Island Hospital IACUC
Animal Care and Use Committee. It should be noted that
theLifespan/RhodeIslandHospitalIACUCAnimalCareand
Use Committee guidelines do not permit animals to die
from experimental disease. Therefore, survival studies could
not be performed, and instead, the rats were sacriﬁced at
predetermined intervals to assess tumor burden.
Rat 9L glioblastoma cells were obtained from the
American Type Culture Collection (Washington, D.C.) and
certiﬁed as pathogen-free. The cells were maintained in Dul-
becco’s Modiﬁed Eagle’s Medium (DMEM) supplemented
with 5% heat-inactivated fetal calf serum (FCS), 2mM
glutamine, and 100μM nonessential amino acids (Gibco-
BRL, Grand Island, NY). Antibiotics were not added to
the medium. Prior to injection, the cells were rinsed with
phosphate-buﬀered saline (PBS), detached from the culture
surfaces and dissociated into single cell suspensions with
0.25% trypsin/0.05% EDTA. The dissociated cells were
washed 3 times in serum-free DMEM and ﬁnally suspended
in serum-free DMEM at a density of 5 × 106 viable cells/mL.
Viable cell density was determined using Trypan blue
exclusion and a hemocytometer chamber.
Rats were divided into 6 treatment groups and all
treatments were either given or initiated on day 6 following
intracerebral 9L cell inoculation. The groups were as follows:
vehicle control (N = 17); low dose (45μg/kg; N = 19)
Talpha1; high dose (200μg/kg; N = 20) Talpha1; low
dose Talpha1+BCNU (N = 18); high dose Talpha1+BCNU
(N = 24); BCNU only (N = 26). BCNU (4.4mg/kg) was
administered as a single intraperitoneal (i.p.) injection. The
indicated doses of Talpha1 were given on 3 consecutive days
by i.p. injection. Human recombinant Talpha1 was used in
theseexperiments.Previousstudiesdemonstratedsigniﬁcant
immuno-modulating eﬀects of human Talpha1 in rat cells,
both in vivo and in vitro [37]. Two diﬀerent termination
points were used in the experiments, day 17 and day 21
after the 9L cell inoculation. The rats were sacriﬁced by
i.p. injection of 120mg/kg sodium pentobarbital. The brains
were harvested, sectioned, immersion ﬁxed in Histochoice
(Amresco Co., Solon, Ohio), and processed to generate
hematoxylin and eosin stained paraﬃn embedded sections
to evaluate the histopathology.
2.2. In Vitro Studies
2.2.1. Cell Lines and Talpha1 Treatments. To evaluate the
eﬀects Talpha1 on viability, mitochondrial function, and
protein expression, 9L cells were seeded into 96-well plates
at a density of 2 × 104 cells per well. In order to demon-
strate mechanisms of Talpha1 adjuvant cell killing, we
used established tumor cell lines instead of primary brain
tumors because consistency across all assays and within each
experiment was needed. In addition, 9L cells were used for
the in vivo experiments, and it was important to understand
howTalpha1treatmentfacilitatesinhibitionoftumorgrowth
in the brain. After overnight attachment and growth, the
cells were exposed to 10−5 M Talpha1 for 24 hours, and then
evaluated for viability or gene expression. To study chronic
eﬀects of Talpha1 treatment, cells seeded in 75-mm2 ﬂasks
were exposed to 3 consecutive daily treatments of 10−5 M
Talpha1 (added to fresh medium), after which the cells were
trypsinized and reseeded into 96-well plates at a density
of 2 × 104 viable cells per well. After 24 hours of further
Talpha1 treatment, the cells were evaluated for viability or
gene expression. The optimum concentration of Talpha1 was
determined from initial dose-toxicity studies in which 9L
cells and postmitotic primary rat cortical neuron cultures
weretreatedwithdiﬀerentconcentrationsofTalpha1ranging
from 10nM to 50μM. Primary cortical neuron cultures were
studied to enable selection of Talpha1 doses that would not
be toxic to nonneoplastic brain cells. Cell viability and mito-
chondrial function were measured using the Crystal violet
(CV) and MTT assays, respectively, since previous studies
showed that CV and MTT absorbances increase linearly with
cell density from 1 × 104 to 5 × 105 cells per well [38–40].
The studies were extended to determine if Talpha1 treatment
increased cellular sensitivity to oxidative stress or BCNU
by exposing the Talpha1-treated cells to H2O2 (100μM) or
BCNU (25μM) for 24 hours, and evaluating viability and
mitochondrial function using the CV and MTT assays.
2.2.2. Directional Motility Assay. Directional motility was
measured using Boyden chamber-type culture inserts that
had 8μMp o r em e m b r a n e s[ 41]. The chambers were seatedJournal of Oncology 3
in 24-well plates. 105 viable cells were placed into the upper
chamber in serum-free medium. Medium supplemented
with 1% FCS was placed in the well below to provide a
trophic stimulus for migration. Migration was allowed to
proceedfor4hours.ATPLite(PackardInstrumentCompany,
Meriden, CT) was used to quantify viable cell density
on the upper surface of the membrane (nonmotile), the
undersurface of the membrane (migrated adherent), and
at the bottom of the well (migrated, nonadherent). Brieﬂy,
nonmotile cells were removed from the upper surface
of the membrane using a cotton swab. The cells were
lysed by immediately submerging the swabs into 200μL
of diluted ATP lysis solution in a well of a black 96-well
microplate. Completeness of cell harvesting was monitored
microscopically. Cells adherent to the undersurface of the
membrane were harvested and lysed by submerging the
wiped membrane in 200μL of diluted ATP lysis solution in
a second well of a black microplate. Cells in the well below
the culture insert were resuspended and added directly to
25μL of undiluted ATP lysis solution in a third well of a
black microplate. After 5-minute incubation with agitation
to ensure complete cell lysis, ATPLite substrate (25μL) was
added to each well. The reactions were mixed for 2 min-
utes by gentle platform agitation. Subsequently, the plates
were dark adapted for 5 minutes and then luminescence
was measured in a TopCount Microplate reader (Packard
Instrument Company, Meriden, CT). The percentages of
motile adherent, motile nonadherent, total population of
motile cells were calculated per chamber [41]. For each
experiment, replicates of 4–6 assays were performed, and the
results were analyzed statistically. In preliminary studies, we
demonstrated that ATPLite luminescence increases linearly
with cell number between 103 and 5 × 105 cells, as indicated
by the manufacturer.
2.2.3. Microtiter Immunocytochemical ELISA (MICE) Assay.
The MICE assay is a rapid and sensitive method of qua-
ntifying immunoreactivity in 96-well microcultures and
combines the advantages of the enzyme-linked immunosor-
bent assay with immunocytochemical staining to permit
sensitive in situ quantiﬁcation of protein expression with
values normalized to cell density [38]. Brieﬂy, the ﬁxed
cells were permeabilized with 0.05% saponin in Tris-
buﬀered saline (50mM Tris, pH 7.5, 0.9% NaCl; TBS),
blocked with Superblock-TBS (Pierce, Rockford, IL), and
then incubated overnight at 4◦C with primary antibodies to
proliferating cell nuclear antigen (PCNA), bcl-2, p21/Wwaf-
1, p53, FasL, FasR, TNF-R1, or GAPDH, each diluted to
0.5–1mg/mL in TBS containing 0.05% Tween-20 and 0.5%
bovine serum albumin (TBST-BSA). Immunoreactivity was
detected using horseradish peroxidase conjugated secondary
antibody (Pierce, Rockford, IL) and the TMB soluble
s u b s t r a t e( P i e r c e ,R o c k f o r d ,I L ) .R e a c t i o n sw e r es t o p p e db y
the addition of 1M H2SO4 and absorbances were measured
at 450nm in a Spectracount microplate reader (Packard
Instrument Co., Meriden, CT). Subsequently, cell density
was measured by staining the adherent cells with Coomassie
blue dye and measuring the absorbance of the eluted dye
[38]. The MICE index was the calculated ratio of TMB and
Coomassie blue absorbance measured in the same culture
well. Mean ± S.D. of results obtained from 16 replicate
culture wells was used for intergroup statistical comparisons.
2.2.4. Granzyme-B Experiments. T cells and natural killer
(NK) cells utilize two major cytotoxic pathways including
perforin-granzyme-mediated necrosis and tumor necrosis
factor (TNF) family ligand-mediated apoptosis [42–48].
To determine if the antineoplastic eﬀects of Talpha1 were
mediated through perforin/Granzyme B-induced killing, we
employed a novel in vitro assay that quantiﬁed Granzyme
B-mediated killing with no requirement to add well-
c h a r a c t e r i z e da n da c t i v a t e dc y t o t o x i cTc e l l sa n dN Kc e l l s .
To accomplish this, 9L cells were ﬁrst treated with Talpha1
or vehicle for 24 hours, after which they were harvested,
reseeded into 96-well black plates (7.5×105 cells/75μL/well),
and exposed to 20,000units/mL Streptolysin O (SLO) plus
100ng recombinant Granzyme B (reaction volume 100μL)
for 1 or 3 hours at 37
◦C. The SLO was used in place of
perforin to permeabilize the cells [49], and recombinant
Granzyme B was used to standardize the assay. Control
studies included parallel reactions in which SLO, Granzyme
B, or both were omitted. Viable cell density was measured
using the ATPlite assay (Packard Instrument Company,
Meriden, CT), which has a broad linear dynamic range
correlating relative light units with cell densities between 103
to 106 c e l l sp e rc u l t u r ew e l l .
2.2.5. Source of Reagents. Recombinant human Talpha1 was
provided as a gift from Sciclone, Inc. (San Francisco,
CA). Monoclonal antibodies to PCNA, p53, bcl-2, FasR,
FasL, TNF-R1, and p21 were purchased from Santa Cruz
biotechnology, Inc., (Santa Cruz, CA), and monoclonal
antibodies to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were purchased from Chemicon International,
Inc. (Temecula, CA). Granzyme B was obtained from
CalBiochem (Carlsbad, CA). Streptolysin O was purchased
from Sigma-Aldrich, St. Louis, MO.
2.2.6. Statistical Analysis. Data depicted in the graphs rep-
resent the mean ± S.D. of results. Intergroup comparisons
were made with the Student’s t-test or analysis of variance
and the Fisher Least Signiﬁcance post hoc signiﬁcance test
using the Number Cruncher Statistical Systems (Dr. Jerry L.
Hintze, Kaysville, UT).
3. Results
3.1. Glioblastoma Model. Intracerebral inoculation of adult
Long Evans rats with 10,000 9L rat glioblastoma cells
consistently produced tumors that progressively enlarged
and caused death within 21–24 days. In untreated rats, the
time-dependent progression of tumor growth and associated
clinical signs were characterized as follows: (1) increased
physical activity with tumor diameters of 4-5mm at day 7;
(2) hyperresponsiveness by day 14 with tumor diameters of
7-8mm and frequentassociated intratumor hemorrhage;(3)
somnolence with tumor masses of 10–12mm accompanied4 Journal of Oncology
by cerebral herniation by day 21-22. Histological sections
stained with hematoxylin and eosin conﬁrmed the presence
of large tumor masses composed of inﬁltrative malignant
neoplastic cells. Histopathological studies of coronal sections
through the entire cerebrum demonstrated that within the
ﬁrst 24 hours of inoculation, no grossly visible tumor could
be detected. However, after 5 days, the 9L cells had grown
and formed small tumor masses that were localized in
the superﬁcial cortex and overlying leptomeninges. Within
10 days, the tumor masses extended to deeper structures
including the basal ganglia and the walls of the lateral
ventricles and were associated with moderate edema but
no herniation (shift of midline structures). By day 14, the
tumor masses were found to extend deeply within the
cerebral hemispheres and occupy nearly 50% of the cross-
sectional area of the section with associated edema and early
herniation. Despite the large size, the demarcation between
tumor mass and cerebral parenchyma remained sharp. By
day 21 or 22, the tumor masses occupied nearly the entire
right frontal lobe with variable degrees of extension to the
contra-lateral hemisphere. The extensive tumor mass was
associated with marked cerebral edema, hemorrhage, and
herniation.
3.2. Eﬀects of Talpha1 and BCNU on Glioblastoma Growth
(Figure 1). A semiquantitative histological grading scale was
used to assess tumor burden for intergroup comparisons:
0: no residual tumor; 1: microscopic tumor conﬁned to the
superﬁcial cortex; 2: tumor mass occupying less than 25% of
the hemisphere cross section; 3: tumor mass occupying up
to 50% of the hemispheric cross-section and extending into
deep structures; 4: massive tumor burden with involvement
of 50–90% of the ipsilateral hemispheric cross-section with
extension of tumor across the midline into the contralateral
hemisphere. The sections were coded and graded simulta-
neously by two of the investigators (SMD and AS) without
knowledge of treatment group. To verify consistency in the
grading, all samples were shuﬄed and rereviewed under
code.
Since spontaneous tumor rejections were not observed
in preliminary studies, all experiments were terminated on
days 17 or 21 after 9L cell implantation. Representative
data from one of the experiments (replicated 3 times) are
shown in Figure 3. Using the standardized grading scheme
to assess tumor burden, we demonstrated that 100% of
vehicle-treated rats had Grade 4 tumor burdens by day
17 (Figure 1), similar to the eﬀects of no treatment (data
not shown). In contrast, rats treated with BCNU exhibited
signiﬁcant reductions in tumor mass relative to vehicle-
treated controls (P<. 01). On Day 17, the tumor burden
was Grade 2 in 75%, and Grade 3 in 25% of those treated
with BCNU only; whereas on Day 21, 25% of the group
each had Grades 4 or 2 tumor burden, and 50% had Grade
3 tumor burden. In essence, the eﬀectiveness of BCNU
was nonuniform with nearly half the group manifesting no
apparent therapeutic response, while the other half had their
expected tumor burdens reduced by up to 50% relative to
control. Rats treated only with Talpha1 had tumor growth
and clinical deterioration rates that were similar to control
(data not shown). In addition, rats treated only with either
the 45μg/kg and 200μg/kg doses of Talpha1, the clinical
course was complicated by extreme intracerebral swelling
and substantially greater degrees of herniation (brain tissue
protruding through the Burr hole) compared with all other
groups. Similarly, in rats treated with BCNU+200μg/kg
of Talpha1, marked degrees of cerebral swelling caused
increased morbidity and mortality. Therefore, studies using
Talpha1 alone or 200μg/kg Talpha1+BCNU were discontin-
ued. Remarkably, the 45μg/kg Talpha1+BCNU group had
signiﬁcantly lower mean tumor burdens relative to vehicle-
treated and BCNU-treated rats, at both the 17 and 21 days
time points (P<. 001; see Figure 1). On Day 17, 44.4% of
those cases exhibited Grade 2 tumor burden, 33.3% Grade 1,
and 22.2% were cured. On Day 21, 20% had Grade 3 tumor
burdens, 40% had Grade 2 tumor burdens, 13.3% had Grade
1tumorburdens,and26%werecured.Cureratesamongrats
treated with Talpha1+BCNU were signiﬁcantly higher than
all other groups (P<. 001).
Histopathological studies were used to evaluate the
eﬀects of BCNU and Talpha1+BCNU in relation to tumor
growth in vivo. In vehicle-treated control rats, the tumors
grew as densely cellular neoplasms with foci of spontaneous
necrosis, frequent mitoses, prominent nuclear pleomor-
phism (variability in cell size and shape), and irregularly
inﬁltrating borders (data not shown). In BCNU-treated
rats in which tumor growth was reduced, the histopatho-
logical studies revealed larger foci of tumor necrosis with
accompanying mononuclear inﬂammatory cell inﬁltrates
composed of macrophages and lymphocytes. In rats treated
with 45mg/kg Talpha1+BCNU, the marked reductions in
tumor burden were associated with large areas of cavitary
necrosis and accompanying mononuclear inﬂammatory cell
inﬁltrates composed of macrophages and lymphocytes. In
cases where no residual tumor was found, only small scars
or cavities marked the location of the previous tumors.
3.3. Eﬀe c t so fT a l p h a 1o n9 LC e l lV i a b i l i t y .In vitro experi-
ments were conducted to determine if the in vivo eﬀects of
Talpha1 on 9L glioblastoma cell growth were mediated by
direct cytotoxic actions or indirect mechanisms. To perform
these studies, 9L cells were seeded in 96-well plates and
exposed to Talpha1 for 24 hours, after which the cultures
were analyzed for viability using the Crystal violet assay, and
mitochondrial function using the MTT assay. Mitochondrial
functionwasmeasuredbecausecelldeathcanbemediatedby
mitochondrialdysfunctionratherthanapoptosisornecrosis.
Although slight dose-dependent reductions in viability and
MTT activity were observed, the overall cytotoxic eﬀects
of the Talpha1 were relatively modest (Figure 2(a)). Similar
resultswereobtainedwithrespecttoprimarycorticalneuron
cultures (Figure 2(b)), as well as other cell lines, including
293 kidney cells and SH-Sy5y neuroblastoma cells (data not
shown). It is noteworthy that the highest concentration of
Talpha1 used in the in vitro experiments (50mM), which
produced 20% declines in the mean levels of viability and
mitochondrial function, was nearly 1000-fold higher thanJournal of Oncology 5
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Figure 1: Analysis of tumor burden in rats treated with vehicle (control), BCNU (4.4mg/kg), or BCNU (4.4mg/kg)+Talpha1 (45mg/kg).
(a) depicts results obtained 17 days after tumor cell implantation. (b) depicts results obtained 21 days after tumor cell implantation. Each
dot represents an individual rat case. Closed circles on the 0 line indicate cures. The horizontal bars correspond to the group mean score.
Intergroup statistical comparisons demonstrated signiﬁcantly lower tumor burdens in BCNU-treated relative to control (∗P<. 01), and
between Talpha1 and control (P<. 001
∗∗)o rB C N U - t r e a t e dr a t s( P<. 01
∗∗).
the doses used for in vivo experiments in which tumor bur-
dens were observed to be substantially reduced. These results
indicate that Talpha1 does not have direct cytotoxic eﬀects
on 9L glioblastoma cells, and that other factors contributed
to the adjuvant therapeutic eﬀects observed in vivo.
3.4. Studies of Talpha1 Eﬀects on 9L Cell Motility. Directional
motility assays were used to determine if the growth
inhibitory eﬀects of Talpha1 were mediated by reduced
cell motility and invasiveness. The ATP-Luminescence-based
motility assay enables quantiﬁcation of the total percent-
ages of migrated cells, as well as the percentages of the
migrated adherent and migrated nonadherent subpopula-
tions. Treatment with Talpha1 did not signiﬁcantly alter
9L cell motility or adhesiveness (percentage of migrated-
adherent cells) (Figure 2(c)). Similarly, in further studies
using human 293 kidney or human SH-Sy5y neuroblastoma
cells, Talpha1 treatment was found to have no signiﬁcant
eﬀect on directional motility or cell adhesion (data not
shown).Therefore,itisunlikelythatthereducedtumormass
in Talpha1-treated rats was due to inhibition of tumor cell
migration, adhesion, or invasive growth.
3.5. Eﬀects of Talpha1 on Proapoptosis and Prosurvival Gene
Expression. Since Talpha1 did not have direct cytotoxic
eﬀects, we explored other potential mechanisms by which
Talpha1 could function to inhibit growth of glioblastomas.
In this regard, we examined the expression of gene products
that promote either apoptosis or cell survival, and assessed
housekeeping gene expression as control. The studies were
performed in 96-well plates using the microtiter immuno-
cytochemical ELISA (MICE) assay to generate data from
multiple replicate cultures. Talpha1 treatment for 24 hours
resulted in signiﬁcantly increased levels of FasR (44.1%),
FasL (65.9%), and TNF-R1 (22.2%) relative to vehicle-
treated controls (P<. 01; see Figure 3). In contrast, expres-
sion levels of bcl-2, p21/waf1, p53, proliferating cell nuclear
antigen (PCNA), and glyceraldehy-3-phosphate dehydro-
genase (GAPDH) were not signiﬁcantly aﬀected by the
Talpha1 treatment. Similar studies performed with human
293 kidney or SH-Sy5y neuroblastoma cells demonstrated
signiﬁcant reductions in bcl-2 (42% and 36.7%, resp.; P<
.01), but no signiﬁcant changes in the levels of FasR, FasL, or
TNF-R1 expression (data not shown).
3.6. Talpha1 Increases 9L Cell Sensitivity to Oxidative Stress
and BCNU Treatment. Activation of proapoptosis mech-
anisms or inhibition of survival pathways could increase
cellular sensitivity to oxidative stress and cytotoxic agents.
Therefore, studies were conducted to determine if Talpha1-
treated cells were rendered more sensitive to oxidative stress
or killing by BCNU. Cells treated with 100mM H2O2 or
10mM Talpha1 exhibited similar mean levels of viability
relative to vehicle-treated control cells (Figure 4). Treatment
with BCNU alone resulted in 28% cell loss relative to control
(P<. 01). Pretreatment with Talpha1 for 24 hours resulted
in signiﬁcantly reduced viability in cultures that were subse-
quently exposed to a sublethal dose (100mM) of H2O2 (P<
.01),andsigniﬁcantlygreatercelllossinculturestreatedwith
Talpha1+BCNU compared with cultures that were treated6 Journal of Oncology
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Figure 2: Talpha1 is not directly cytotoxic for (a) rat 9L glioblastoma cells or (b) normal rat cortical neurons, and (c) does not inhibit
cell migration. 9L cells and cortical neurons were cultured in 96-well plates and treated with diﬀerent concentrations of Talpha1. Viability
was measured using the Crystal violet assay, and mitochondrial function was measured using the MTT assay. Both the 9L cells and cortical
neurons remained viable and exhibited minimal reductions in mitochondrial function over a broad range of Tapha1 exposure. In cultures
treated with 50mM Talpha1 (highest dose used), both cell types exhibited approximately 20% reductions in MTT and CV indices; however,
that concentration was considerably higher than the amounts used for the in vivo experiments. (c) In vitro motility assays were performed
using 9L cells that were treated with vehicle or Talpha1 (10mM) for 24 hours. Motility was measured using the ATP Luminescence-Based
Motility/Invasion assay (see Methods). The percentages of total migrated, nonmigrated, migrated-adherent (passed through the pores and
remained adherent to the undersurface of the membrane), and migrated nonadherent cells (passed through the pores and landed at the
bottom of the chamber) were calculated, and the means ± S.D.s of the results are depicted graphically.
with BCNU only (P<. 01), or H2O2, Talpha1, or vehicle
(P<. 001)(Figure 4).Similarresultswereobtainedusing293
or C6 glioma cells as targets in the assay (data not shown).
3.7. Talpha1 Increases 9L Cell Sensitivity to Granzyme
B-Mediated Killing. In vivo malignant neoplastic cells
are killed by cytotoxic T cells and macrophages that are
recruited by proinﬂammatory cytokines such as IL-2 and
IL-12. Cytotoxic T cells kill by releasing perforin, which
generates holes in target cell membranes, and Granzyme B,
which causes enzymatic destruction and death of the target
cells. To study the potential role of Talpha1 in enhancing T
cell-mediated killing of 9L glioblastoma cells, we constructed
an in vitro assay in which Talpha1- or vehicle-treated 9L cells
were incubated with Granzyme B in the presence or absence
of Streptolysin O (permeabilizing agent) for 1 or 3 hours.
Viability was measured using the ATP luminescence assay
a n dw i t h i ng r o u pc o m p a r i s o n sw e r em a d et od e t e r m i n et h e
relative killing associated with SLO+Granzyme B treatment.
The studies demonstrated signiﬁcant reductions in cell
viability in Talpha1-treated cultures that were exposed
to SLO+Granzyme B relative to Talpha1-treated culturesJournal of Oncology 7
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Figure 3: Increased proapoptosis gene products in Talpha1-treated
9L glioblastoma cells. 9L cells seeded in 96-well plates were
treated with 10mM Talpha1 for 24 hours. After ﬁxation and
permeabilization, immunoreactivity was measured directly in the
cells using the microtiter immunocytochemical ELISA (MICE)
assay. Levels of immunoreactivity were normalized to cell density
and the corresponding ratio represents the MICE index. The graph
depicts the mean ± S.D. of the levels of proliferating cell nuclear
antigen (PCNA), Bcl-2, p21, p53, Fas L, Fas R, tumor necrosis
factor receptor, type 1 (TNF R1), and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) measured in 8 replicate vehicle-treated
or Talpha1-treated cultures. Asterisks denote signiﬁcant diﬀerences
from control (P<. 01).
exposed to SLO, Granzyme B, or vehicle only (P<. 001;
Figure 5). In addition, Granzyme B-mediated killing
progressed over time as evidenced by the substantially
greater degrees of cell loss observed in assays performed after
3 hours compared to 0.1- or 1-hour incubation (Figure 5).
In addition, after 3 hours of incubation, cultures treated with
Talpha1+Granzyme B also had reduced viability relative
to control (P<. 05), suggesting modest slow (ineﬃcient)
cellular entry of Granzyme B in the absence of SLO.
4. Discussion
Glioblastomas are highly aggressive primary CNS malignant
neoplasms that kill by widespread inﬁltration of the brain
parenchyma and mass eﬀect. Despite a number of advances
in understanding the molecular genetics of these neoplasms
and in devising novel treatments, a major barrier for achiev-
ing eﬀective disease control or cure is the generally lackluster
host immune response to the neoplastic cells. Due to their
inﬁltrative growth patterns, it will probably never be possible
to achieve total curative surgical excision of glioblastomas,
and therefore other approaches must be utilized. However,
even with the application of high-dose chemotherapy or
radiation, the host response is critical for removing debris
and eradicating small populations of residual and newly
arising neoplastic cells. With glioblastomas, suboptimal
function of this eﬀector arm may account for the repeated
and rapid recurrences of tumor following apparently suc-
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Figure 4: Talpha1 increased 9L cell sensitivity to oxidative stress
and BCNU killing. 9L cells were seeded in 96-well plates. After
overnightattachmentandgrowth,cellswerepretreatedwith10mM
Talpha1 (Ta1) or vehicle. 12 hours later, the medium was changed
andcellsweretreatedwithvehicle(control),0.1mMH2O2,Talpha1
only (Ta1), Talpha1+H2O2, BCNU (25mM), or Talpha1+BCNU.
Viability was measured in 12 replicate cultures using the crystal
violet assay. The graph depicts the mean ± S.D. of results. Asterisks
indicate signiﬁcant diﬀerences (P<. 01) from vehicle-treated
control, H2O2-treated, and Talpha1-only treated cultures.
cessful treatment. In this regard, recent evidence indicates
that immune modulator therapy may prolong survival and
promote glioblastoma killing in vivo.
Talpha1 (Thymosin-α1) is a 28-amino acid peptide
representing a synthetic form of a naturally occurring
compound found in circulation [14, 15]. Talpha1 stimulates
thymocyte growth and diﬀerentiation, production of IL-
2, T-cell IL-2 receptors, IFN-γ and IFN-α [16–24, 26, 50].
Talpha1 has been used in clinical trials to treat hepatitis
B and C infections [13, 27–33], carcinomas of the head
and neck, lung cancer, and malignant melanoma [14, 15,
35], cytomegalovirus infection following renal transplant
[36], and AIDS [13]. The promising results of these clinical
investigations, combined with the evidence of reduced T-
cell responsiveness to glioblastomas, led to the present
work evaluating the potential therapeutic beneﬁt of Talpha1
immunotherapy for treating malignant gliomas and deter-
mining the mechanisms in which Talpha1 exerts its anti-
neoplastic eﬀects. Further interest in the potential adjuvant
use of Talpha1 for treating malignant gliomas stems from
the facts that (1) it represents a synthetic puriﬁed version
of a endogenously produced compound and thus minimal
evidence can be found of clinical toxicity in humans;
(2) previous independent work demonstrated that Talpha1
stimulatesproductionofproinﬂammatorycytokines [17–22,
26, 50–55], which provide a therapeutic beneﬁt in slowing
the progression of experimental malignant glial neoplasms.8 Journal of Oncology
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Figure 5: Talpha1 enhances Granzyme B-mediated killing of 9L
glioblastoma cells. 9L cells were pretreated with vehicle or Talpha1
for 3 hours. The cells were then divided and further treated
with vehicle, Streptolysin O (permeabilizing agent to substitute
for Perforin), Granzyme B only, or Granzyme B+Streptolysin O.
After 0.1, 1, or 3 hours of incubation, the cells were harvested
to determine viability (resistance to killing). Each experiment was
performed in replicates of 4, and cell viability, measured with the
ATP luminescence, was assayed in replicates of 6 or 8 ∗P<. 001 and
∗P<. 05 relative to control.
The in vivo studies using an experimental model of
glioblastoma demonstrated that while BCNU treatment
did signiﬁcantly reduce tumor burden, the responses were
heterogeneous with several cases exhibiting no detectable
eﬀect relative to vehicle-treated controls. However, treat-
ment with Talpha1+BCNU provided signiﬁcant therapeutic
beneﬁt both with respect to reducing mean tumor burden
and curing tumors in approximately 25% of the cases. The
Talpha1+BCNU-mediated reductions in tumor burden were
associated with increased tumor cell necrosis accompanied
by lympho-mononuclear cell inﬁltrates within and around
the residual mass of neoplastic cells in the brain. In cases
where no residual tumor could be found, only gliotic scars
or cavitated foci with associated scant inﬂammation were
detected.Glioblastomacureswereobservedinapproximately
25% of the low-dose (45mg/kg) Talpha1+BCNU treated
group.
A somewhat unexpected ﬁnding was that the Talpha1-
only groups, and rats treated with 200 mg/kg Tal-
pha1+BCNU fared the same as control or worse. Frequently,
the brains of Talpha1-only treated rats were more swollen
and herniated due to inﬂammation and edema combined
with the growing tumor mass. In this regard, it is noteworthy
that rats treated with the lower concentration of Talpha1
± BCNU had better outcomes than those treated with the
higher concentration of Talpha1 ± BCNU since the tumor
cell killing was similar, but edema and herniation were
more prevalent and pronounced in the group that received
the higher concentration of Talpha1. Therefore, Talpha1
treatment alone did not eradicate the glioblastomas, and
at the higher dose tested, it proved detrimental due to the
excess swelling in the absence of concomitant chemotherapy.
Further research regarding dose eﬀectiveness and safety
margins will be required for translation of these results
to the human clinical setting. The results further suggest
that Talpha1 had little or no direct cytotoxic eﬀects on
malignant neoplastic cells, and that the additional tumor
cell killing observed with Talpha1+BCNU treatment was
mediated by indirect actions of Talpha1. Since there were no
apparentdiﬀerencesinthedensitiesoflympho-mononuclear
cells inﬁltrating the tumors, it is unlikely that the Talpha1-
mediated eﬀects were due to recruitment of inﬂammatory
cells. Therefore, we elected not to pursue extensive analysis
of the inﬂammatory cell inﬁltrates using the in vivo model.
Moreover, we anticipated that such data would be skewed by
diﬀerences in tissue swelling and tumor necrosis associated
with the diﬀerent treatments. Instead, in vitro experiments
were conducted to clarify the potential mechanism by which
Talpha1 enhanced the cytotoxic actions of BCNU against
glioblastoma cells.
The in vitro studies demonstrated that Talpha1 had no
signiﬁcant direct cytotoxic eﬀects on the glioblastoma cells,
consistent with the in vivo ﬁndings. Similar results were
obtained with respect to other cell types including SH-Sy5y
neuroblastoma cells, 293 kidney cells, C6 glioma cells, and
postmitotic cortical neurons. However, it was eﬀective in
reducing tumor volume when administered with BCNU via
mechanisms that did not involve increased inﬂammation
or impairments in cell motility/invasiveness. Therefore,
we hypothesized that as an adjuvant agent, Talpha1 may
help mediate tumor cell killing by enhancing activation
of proapoptosis or oxidative stress pathways. To extend
these investigations, we evaluated whether Talpha1 adversely
aﬀected cell function and perhaps rendered the cells more
sensitive to injurious agents including oxidants. This was
done by examining the expression levels of proapoptosis
and prosurvival genes, as well as growth and housekeeping
genes. Those studies revealed that Talpha1 treatment for as
little as 24 hours resulted in signiﬁcantly increase levels of
proapoptosis genes in 9L glioblastoma cells. Similar results
were obtained with C6 glioma cells; whereas in SH-Sy5y
neuroblastoma and 293 kidney cells, Talpha1 treatment
inhibited prosurvival mechanisms rather than stimulate
proapoptosis genes. These ﬁndings in aggregate suggest that,
although Talpha1 has no direct cytotoxic eﬀects, it may
render neoplastic cells more sensitive to cytotoxic agents by
increasing the expression of proapoptosis genes or reducing
expression of survival genes. To test this hypothesis, we
determined if Talpha1-treated cells were more sensitive to
oxidative stress or BCNU-mediated killing. The studies
showed that after 24 hours of Talpha1 treatment, sublethal
concentrations of H2O2 or BCNU, respectively, killed 25%
or 40% of the 9L cells. Therefore, at least some of the
eﬀects of Talpha1 were mediated by its actions on the
neoplastic cells rather than by immune modulation andJournal of Oncology 9
recruitment/activationofTcells,NKcells,andmacrophages.
Although the mechanism of these eﬀects is not known,
the ﬁndings in previous reports suggest that Talpha1 can
have direct eﬀects on the biological function of nonimmune
cells [25, 56–59], including inhibition of neoplastic neural
and glial cell proliferation [24, 25], enhancement of the
proapoptosis actions of compounds such as retinoic acid
[56], and promoting the conversion of Cytochrome C
from an antioxidant to pro-oxidant form of the molecule
[57]. The latter may represent the mechanism by which
Talpha1increased the proapoptosis gene expression in the 9L
glioblastoma cells.
The immune-modulating properties of Talpha1 and
relatedmoleculeshavebeenwellestablished.Itsmajoreﬀects
are to increase proinﬂammatory cytokine production and
lymphocyteproliferation.ActivatedTlymphocyteskilltarget
cells through FasL-FasR interactions and by activating the
perforin-granzyme system. The ﬁnding of increased FasL
and FasR expression in Talpha1-treated 9L glioblastoma cells
suggests that activated T cells could eﬀectively kill these
target cells though FasL/FasR interactions. Utilizing a novel
in vitro assay constructed with SLO (permeabilizing agent)
and recombinant Granzyme B instead of activated T cells,
we demonstrated that Talpha1-treated 9L glioblastoma cells
were rapidly killed by exposure to SLO and Granzyme B.
These ﬁndings suggest that Talpha1 may eﬀectively promote
immune-mediated killing of glioblastoma cells in several
ways: (1) increasing basal levels of proapoptosis gene expres-
sion rendering the cells more sensitive to oxidative stress and
cytotoxic/chemotherapeutic agents; (2) increasing levels of
FasR which could interact with FasL on activated T cells
or NK cells and lead to increased apoptosis; (3) enhancing
perforin-granzyme-mediated killing of target tumor cells. In
addition, the results strongly indicate that Talpha1 treatment
of glioblastomas is eﬀective when used in combination with
BCNU, but not as a stand-alone agent. The results provide
substantial evidence that Talpha1 administered alone may be
detrimentalduetoincreasedswellingandinﬂammationwith
minimal tumor cell eradication. Therefore, the most suitable
role for Talpha1 in the treatment of glioblastomas is as an
adjuvant agent for boosting the host immune response and
eradicating residual tumor cells that survive conventional
chemotherapy.
In conclusion, the work described herein demonstrates
that Talpha1 exhibits antiglioblastoma eﬀects that are medi-
ated through several channels including: (1) modulation of
proapoptosis/survival genes leading to increased tumor cell
sensitivity to oxidative stress or cytotoxic/chemotherapeutic
agents; (2) promoting FasR-FasL-mediated immune cell
killing cascades; (3) increasing target cell sensitivity to
perforin-granzyme-mediated immune cell killing. The ﬁnd-
ing that the therapeutic eﬀects of Talpha1 with respect
to its antiglioblastoma properties were dependent upon
the concomitant administration of BCNU emphasizes that
Talpha1 would be best suited as an adjuvant immune
modulator rather than a deﬁnitive antineoplastic agent. It is
also likely that when combined with other chemotherapeutic
compounds, Talpha1 could have similar positive eﬀects in
helping to reduce tumor burden, progression, and recur-
rences at signiﬁcantly greater rates than currently observed
with conventional chemotherapy.
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